OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Neelapu on Addressing CAR T-Cell Resistance in Lymphoma

May 22nd 2024

Sattva S. Neelapu, MD, discusses mechanisms of resistance to CAR T-cell therapies in lymphoma and how these areas of need may be addressed.

Dr Jagannath on Safety Considerations With Ide-Cel in Multiple Myeloma

May 20th 2024

Sundar Jagannath, MBBS, discusses the FDA’s ODAC Meeting on safety considerations with ide-cel in multiple myeloma.

Dr Maxwell on the Accessibility of Genetic Testing in Metastatic Prostate Cancer

May 20th 2024

Kara N. Maxwell, MD, PhD, discusses the accessibility of genetic testing in the community setting for patients with metastatic prostate cancer.

Dr Lim on the Treatment of Resectable and Borderline Resectable Pancreatic Cancer

May 20th 2024

Kian-Huat Lim, MD, PhD, discusses the current standard of care for patients with resectable or borderline resectable pancreatic cancer.

Dr Kelly on ctDNA Dynamics Following Neoadjuvant Immunotherapy in GEJ Cancer

May 20th 2024

Ronan J. Kelly, MD, MBA, FASCO, discusses the predictive value of ctDNA following neoadjuvant immunotherapy in resectable gastroesophageal cancer.

Dr Salani on Research With MEK Inhibition in KRAS-Mutant Serous Ovarian Cancer

May 20th 2024

Ritu Salani, MD, MBA, discusses pathways implicated in low-grade serous ovarian cancer that may be viable for targeted therapy development.

Dr Lattanzi on Findings From the PROpel trial in mCRPC

May 17th 2024

Mike Lattanzi, MD, discusses key findings from and implications of the PROpel trial in patients with metastatic castration-resistant prostate cancer.

Dr Narayan on Long-Term Results With Nadofaragene Firadenovec in NMIBC

May 17th 2024

Vikram M. Narayan, MD, discusses the final 5-year analysis of a phase 3 trial of nadofaragene firadenovec in patients with BCG-unresponsive NMIBC.

Dr Liu Previews ASCO 2024 Lung Cancer Data

May 17th 2024

Stephen V. Liu, MD, discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC.

Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma

May 17th 2024

S. Vincent Rajkumar, MD, discusses highly anticipated abstracts in multiple myeloma that will be presented at the 2024 ASCO Annual Meeting.

Dr Kasi on the Potential Implications of ctDNA presence in Colorectal Cancer

May 17th 2024

Pashtoon Murtaza Kasi, MD, MS, discusses the potential implications of ctDNA on clinical practice in treating/diagnosing colorectal cancer.

Dr Gangat on JAK Inhibitor Selection in Treatment-Naive Myelofibrosis

May 17th 2024

Naseema Gangat, MBBS discusses the clinical utility of momelotinib and JAK inhibitor selection in treatment-naive myelofibrosis.

Dr Obeng-Gyasi on Neighborhood Opportunity and Mortality in Breast Cancer

May 16th 2024

Samilia Obeng-Gyasi, MD, MPH, discusses a retrospective study on neighborhood opportunity and all-cause mortality in patients with breast cancer.

Dr Lim on Treatment With FOLFIRINOX vs NALIRIFOX in Metastatic Pancreatic Cancer

May 16th 2024

Kian-Huat Lim, MD, PhD, discusses factors influencing the choice between treatment with FOLFIRINOX or NALIRIFOX for metastatic pancreatic cancer.

Dr Dahiya on the FDA Approval of Liso-Cel for Relapsed/Refractory Follicular Lymphoma

May 16th 2024

Saurabh Dahiya, MD, FACP, discusses the FDA approval of lisocabtagene maraleucel for patients with relapsed/refractory follicular lymphoma.

Dr Baljevic on Advancements in the Management of Newly Diagnosed Multiple Myeloma

May 16th 2024

Muhamed Baljevic, MD, discusses key trial updates and advancements with quadruplet therapy in newly diagnosed multiple myeloma.

Dr Jagannath on the ODAC Meeting on the Safety of Cilta-Cel in R/R Multiple Myeloma

May 16th 2024

Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.

Dr Gopal on a Case Study of a Patient With Bladder Cancer

May 16th 2024

Nikhil Gopal, MD, discusses details from a case discussion of a patient with bladder cancer.

Dr Kishtagari on the Impact of Momelotinib on the Management of Anemic Myelofibrosis

May 16th 2024

Ashwin Kishtagari, MD, discusses how momelotinib addresses unmet needs in the management of anemic myelofibrosis following disease progression on ruxolitinib.

Dr Ball on Data From from the IMerge Trial in Low– to Intermediate-Risk MDS

May 16th 2024

Somedeb Ball, MBBS, discusses data from the phase 3 IMerge trial of imetelstat vs placebo in low– to intermediate-risk myelodysplastic syndromes.